Valley Medical Pharmacy 
630 Main Street 
Brawley, CA 92227 
eRx ID#0585957 
1 (800) 322-0808 | Toll Free Fax: 1 (855) 322-0808 
Email: drugsdepot@yahoo.com 
Web: www.drugsdepot 
Timing: Monday to Friday | 9:00 AM to 5:45 PM 


Necon 0.5-0.035 Mg Tabs 6X28 By Actavis Pharma

Image 0 of Necon 0.5-0.035 Mg Tabs 6X28 By Actavis PharmaImage 1 of Necon 0.5-0.035 Mg Tabs 6X28 By Actavis Pharma

Necon 0.5-0.035 Mg Tabs 6X28 By Actavis Pharma

Call for Price

Necon 0.5-0.035 Mg Tabs 6X28 By Actavis Pharma This Item Requires A Valid Order From A Physician Licensed in USA. Item Number.:RXD2435667/RXB10017237
Size : 6X28
Selling UoM : PK
NDC: 52544-0550-28
UPC Barcode : 352544550283
Supplier: 0050000679 ACTAVIS PHARMA INC/GENERIC
Supplier Material : 055028
Generic Code : 003294 NORETHINDRONE-ETHINYL ESTRAD ORAL TABLET
Fine Line Class : 850085008510 All Rx Products
Product Category : RX Pharmaceuticals
Product Type : GRX Generic

Have a question?

  Call for Price

Product Description.:

WATSON, 507 or P
tablet , multi-colored , round round
21 light yellow (507), 7 white (P)

Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases.
DRUG DESCRIPTION

Each of the following products is a combination oral contraceptive containing the progestational compound norethindrone and the estrogenic compound ethinyl estradiol:

Necon? 1/35: Each dark yellow tablet contains 1 mg of norethindrone and 0.035 mg of ethinyl estradiol. Inactive ingredients include D&C Yellow No. 10 Aluminum Lake, microcrystalline cellulose, lactose (anhydrous), magnesium stearate, polacrilin potassium, and povidone. Each white tablet in the Necon? 1/35 package contains only inert ingredients, as follows: micro- crystalline cellulose, lactose (anhydrous), and magnesium stearate.

Necon? 0.5/35: Each light yellow tablet contains 0.5 mg of norethindrone and 0.035 mg of ethinyl estradiol. Inactive ingredients include D&C Yellow No. 10 Aluminum Lake, microcrystalline cellulose, lactose (anhydrous), magnesium stearate, polacrilin potassium, and povidone. Each white tablet in the Necon? 0.5/35 package contains only inert ingredients as listed under white tablets in Necon? 1/35.

Necon? 10/11: Each light yellow tablet (10) contains 0.5 mg of norethindrone and 0.035 mg of ethinyl estradiol. Each dark yellow tablet (11) contains 1 mg of norethindrone and 0.035 mg of ethinyl estradiol. Inactive ingredients include D&C Yellow No. 10 Aluminum Lake, microcrys- talline cellulose, lactose (anhydrous), magnesium stearate, polacrilin potassium, and povidone. Each white tablet in the Necon? 10/11 package contains only inert ingredients as listed under white tablets in Necon? 1/35.

Each of the following products is a combination oral contraceptive containing the progestational compound norethindrone and the estrogenic compound mestranol:

Necon? 1/50: Each light blue tablet contains 1 mg of norethindrone and 0.05 mg of mestranol. Inactive ingredients include FD&C Blue No. 1 Aluminum Lake, microcrystalline cellulose, lactose (anhydrous), magnesium stearate, polacrilin potassium, and povidone. Each white tablet in the Necon? 1/50 package contains only inert ingredients as listed under white tablets in Necon? 1/35.

INDICATIONS

Necon? 1/35, Necon? 0.5/35, Necon? 10/11, and Necon? 1/50 are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. Oral contraceptives are highly effective. Table I lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates.

SIDE EFFECTS

An increased risk of the following serious adverse reactions has been associated with the use of oral contraceptives (see WARNINGS section).

* Thrombophlebitis and venous thrombosis with or without embolism
* Arterial thromboembolism
* Pulmonary embolism
* Myocardial infarction
* Cerebral hemorrhage
* Cerebral thrombosis
* Hypertension
* Gallbladder disease
* Hepatic adenomas or benign liver tumors

The following adverse reactions have been reported in patients receiving oral contraceptives and are believed to be drug-related:

* Nausea
* Vomiting
* Gastrointestinal symptoms (such as abdomi- nal cramps and bloating)
* Breakthrough bleeding
* Spotting
* Change in menstrual flow
* Amenorrhea
* Temporary infertility after discontinuation of treatment
* Edema
* Melasma which may persist
* Breast changes: tenderness, enlargement, secretion
* Change in weight (increase or decrease)
* Change in cervical erosion or secretion
* Diminution in lactation when given immediately postpartum
* Cholestatic jaundice
* Migraine
* Rash (allergic)
* Mental depression
* Reduced tolerance to carbohydrates
* Vaginal candidiasis
* Change in corneal curvature (steepening)
* Intolerance to contact lenses